Imunon Inc - Company Profile
Powered by 
All the sales intelligence you need on Imunon Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Imunon Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Imunon Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Imunon Inc (Imunon), formerly Celsion Corp, is a clinical-stage biotechnology company. It focuses on developing treatments that utilize the body's natural mechanisms to address various human diseases. The company's main activities include advancing its non-viral DNA technology across two primary modalities: TheraPlas for immunotherapies and PlaCCine for nucleic acid vaccines. Imunon's major products include the IMNN-001 DNA-based immunotherapy for ovarian cancer and the IMNN-101 COVID-19 booster vaccine. The company is also validating its PlaCCine platform for nucleic acid vaccines against infectious diseases, including SARS-CoV-2. The company's products are designed for applications in oncology and infectious diseases, serving patients with difficult-to-treat conditions. Imunon is headquartered in Lawrenceville, New Jersey, the US.
Headquarters
United States of America
Address
Suite 100, 997 Lenox Drive, Lawrenceville, New Jersey, 08648
Website
www.imunon.com
Telephone
1 609 8969100
No of Employees
20
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IMNN (NASD)
EPS
XYZ
Net Income (2024)
XYZ
22.2%
(2024 vs 2023)
Market Cap*
$7.9M
Net Profit Margin (2021)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Imunon Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | TheraPlas |
| IMNN-001: Ovarian Cancer | PlaCCine |
| IMNN-101: SARS-CoV-2 |
Competitor Comparison
| Key Parameters | Imunon Inc | Merck & Co Inc | Bristol-Myers Squibb Co | Amgen Inc | Zydus Lifesciences Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | India |
| City | Lawrenceville | Rahway | Princeton | Thousand Oaks | Ahmedabad |
| State/Province | New Jersey | New Jersey | New Jersey | California | Gujarat |
| No. of Employees | 20 | 75,000 | 32,500 | 31,500 | 23,283 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael H. Tardugno | Chairman | Executive Board | 2022 | 74 |
| Stacy R. Lindborg, Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2024 | 55 |
| Douglas V. Faller, Ph.D | Chief Medical Officer | Senior Management | 2025 | 72 |
| Khursheed Anwer Ph.D. | Chief Science Officer; Executive Vice President | Senior Management | 2014 | 65 |
| Susan Eylward | Secretary; General Counsel | Senior Management | 2024 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer